Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Newborn screening initiative

This article was originally published in The Gray Sheet

Executive Summary

Healthcare facilities would be able to purchase tandem mass spectrometry systems that test for more newborn genetic and metabolic disorders at lower cost under legislation to be introduced within the next several weeks by Sens. Mike DeWine (R-Ohio) and Chris Dodd (D-Conn.). A General Accounting Office report requested by the senators finds that a majority of states screen for eight or fewer diseases and that "most states spend $20-40 per newborn on screening, most of which is paid for by out-of-pocket screening fees," Dodd's office notes in an April 16 release...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel